Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate Patent Expiration
Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate is Used for maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. It was first introduced by Glaxosmithkline Intellectual Property Development Ltd England
Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate Patents
Given below is the list of patents protecting Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Trelegy Ellipta | US11090294 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | Nov 29, 2030 | Glaxosmithkline |
| Trelegy Ellipta | US6537983 | Anti-inflammatory androstane derivatives |
Aug 03, 2021
(Expired) | Glaxosmithkline |
| Trelegy Ellipta | US6759398 | Anti-inflammatory androstane derivative |
Aug 03, 2021
(Expired) | Glaxosmithkline |
| Trelegy Ellipta | US6878698 | Anti-inflammatory androstane derivatives |
Aug 03, 2021
(Expired) | Glaxosmithkline |
| Trelegy Ellipta | US7101866 | Anti-inflammatory androstane derivative |
Aug 03, 2021
(Expired) | Glaxosmithkline |
| Trelegy Ellipta | US7439393 | Phenethanolamine derivatives for treatment of respiratory diseases | May 21, 2025 | Glaxosmithkline |
| Trelegy Ellipta |
US7439393 (Pediatric) | Phenethanolamine derivatives for treatment of respiratory diseases | Nov 21, 2025 | Glaxosmithkline |
| Trelegy Ellipta | US7488827 | Muscarinic acetylcholine receptor antagonists | Dec 18, 2027 | Glaxosmithkline |
| Trelegy Ellipta | US7498440 | Muscarinic acetylcholine receptor antagonists | Apr 27, 2025 | Glaxosmithkline |
| Trelegy Ellipta | US7629335 | Anti-inflammatory androstane derivative |
Aug 03, 2021
(Expired) | Glaxosmithkline |
| Trelegy Ellipta | US7776895 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep 11, 2022
(Expired) | Glaxosmithkline |
| Trelegy Ellipta | US8113199 | Counter for use with a medicament dispenser | Oct 23, 2027 | Glaxosmithkline |
| Trelegy Ellipta |
US8113199 (Pediatric) | Counter for use with a medicament dispenser | Apr 23, 2028 | Glaxosmithkline |
| Trelegy Ellipta | US8161968 | Medicament dispenser | Feb 05, 2028 | Glaxosmithkline |
| Trelegy Ellipta |
US8161968 (Pediatric) | Medicament dispenser | Aug 05, 2028 | Glaxosmithkline |
| Trelegy Ellipta | US8183257 | Muscarinic acetylcholine receptor antagonists | Jul 27, 2025 | Glaxosmithkline |
| Trelegy Ellipta | US8309572 | Muscarinic acetylcholine receptor antagonists | Apr 27, 2025 | Glaxosmithkline |
| Trelegy Ellipta | US8511304 | Medicament dispenser | Jun 14, 2027 | Glaxosmithkline |
| Trelegy Ellipta |
US8511304 (Pediatric) | Medicament dispenser | Dec 14, 2027 | Glaxosmithkline |
| Trelegy Ellipta | US8534281 | Manifold for use in medicament dispenser | Mar 08, 2030 | Glaxosmithkline |
| Trelegy Ellipta |
US8534281 (Pediatric) | Manifold for use in medicament dispenser | Sep 08, 2030 | Glaxosmithkline |
| Trelegy Ellipta | US8746242 | Medicament dispenser | Oct 11, 2030 | Glaxosmithkline |
| Trelegy Ellipta |
US8746242 (Pediatric) | Medicament dispenser | Apr 11, 2031 | Glaxosmithkline |
| Trelegy Ellipta | US9333310 | Medicament dispenser | Oct 02, 2027 | Glaxosmithkline |
| Trelegy Ellipta |
US9333310 (Pediatric) | Medicament dispenser | Apr 02, 2028 | Glaxosmithkline |
| Trelegy Ellipta | US9750726 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | Nov 29, 2030 | Glaxosmithkline |
| Trelegy Ellipta | USRE44874 | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar 23, 2023
(Expired) | Glaxosmithkline |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳